Related Experiment Videos
Use of a blue filter in visual field analysis
1Department of Ophthalmology, King's Mill Hospital, Sutton-in-Ashfield, Nottinghamshire.
The British Journal of Ophthalmology
|March 1, 1991
Summary
A modified Friedmann visual field test using blue targets effectively differentiates early glaucoma from normal vision. This adaptation aids ophthalmologists in detecting glaucomatous field loss, showing promise for early glaucoma diagnosis.
Area of Science:
- Ophthalmology
- Visual Psychophysics
- Medical Diagnostics
Background:
- Early detection of glaucoma is crucial for preventing vision loss.
- Standard visual field testing may not always distinguish early glaucomatous changes from normal variations.
- The Friedmann visual field analyser is a common tool for perimetry.
Purpose of the Study:
- To evaluate a modified Friedmann visual field test protocol for improved early glaucoma detection.
- To assess the ability of selective blue field scores to differentiate between normal, ocular hypertension, and early glaucoma groups.
Main Methods:
- One hundred twenty-seven eyes from 127 patients were tested using a Kodak 47B Wratten blue filter with the Friedmann Mark 1 visual field analyser.
- Patients were categorized into normal (49), ocular hypertension (50), and early glaucoma (28) groups.
- A derived threshold value for blue targets (selective blue field scores) was analyzed.
Main Results:
- A simple scoring system did not significantly differentiate the three groups.
- Selective blue field scores successfully differentiated normal subjects from those with early glaucomatous field loss.
- The modified test achieved 64% sensitivity and 96% specificity in detecting early glaucoma, with 22% of ocular hypertension patients showing abnormal results.
Conclusions:
- The adaptation of the Friedmann protocol with selective blue field scores shows potential for enhancing early glaucoma detection.
- This modified approach may assist ophthalmologists in confirming early glaucomatous field defects.
- Further validation is warranted to establish its clinical utility in routine glaucoma screening.